Your body has two parallel highways for recycling homocysteine back into methionine. The better-known route depends on folate and B12, governed by MTHFR and MTR. The second — the one BHMT controls — uses betaine as the methyl donor and operates entirely independently of the folate cycle. BHMT¹¹ BHMT
Betaine-homocysteine S-methyltransferase — a zinc-dependent enzyme expressed mainly in liver and kidney is responsible for roughly half of hepatic homocysteine remethylation, making it an essential parallel pathway that buffers the whole methylation cycle.

The R239Q variant (rs3733890) swaps an arginine for a glutamine at position 239 of the enzyme — a change in a region important for substrate coordination. Carriers show measurably lower downstream metabolites, indicating that the A-allele enzyme processes betaine less efficiently.

The Mechanism

BHMT catalyzes the reaction: betaine + homocysteine → dimethylglycine (DMG) + methionine. The arginine-to-glutamine substitution at position 239 (p.Arg239Gln, NM_001713.3:c.716G>A²² NM_001713.3:c.716G>A
Nucleotide 716 in the BHMT coding sequence changes from G to A) alters the enzyme's handling of its substrates. Because betaine flux through BHMT is reduced, less homocysteine is cleared via the betaine route. The body compensates by increasing reliance on the folate/B12-dependent pathway — fine when that pathway is intact, but potentially problematic when MTHFR or MTR variants are also present. The enzyme is expressed predominantly in the liver and kidney, where BHMT accounts for up to 50% of homocysteine remethylation³³ where BHMT accounts for up to 50% of homocysteine remethylation
Finkelstein 1990 — BHMT is responsible for roughly half of hepatic one-carbon transfer in the methionine cycle.

The Evidence

A study of 373 healthy Caucasian adults⁴⁴ study of 373 healthy Caucasian adults
Clifford AJ et al. Gender and SNPs in MTHFR, BHMT, and related genes predict plasma homocysteine. J Nutr, 2012 identified BHMT rs3733890 as one of only six genes that significantly predicted normalized plasma homocysteine levels (p=0.019), underscoring its genuine influence on homocysteine metabolism in healthy individuals.

The metabolite effects are directly measurable. In 1,423 postmenopausal women from the Women's Health Initiative, each A allele was associated with 4.0% lower plasma betaine and 6.75% lower DMG⁵⁵ each A allele was associated with 4.0% lower plasma betaine and 6.75% lower DMG
Ilozumba MN et al. Choline metabolites and genetic polymorphisms in one-carbon metabolism. J Nutr, 2020 — the two compounds immediately upstream and downstream of the BHMT reaction. This dose-response pattern confirms reduced BHMT throughput in A-allele carriers.

In 638 patients with hyperhomocysteinemia, rs3733890 significantly predicted how well individuals responded to folate therapy⁶⁶ rs3733890 significantly predicted how well individuals responded to folate therapy
Li D et al. Genetic and epigenetic regulation of BHMT in hyperhomocysteinaemia. Asia Pac J Clin Nutr, 2019 (p<0.05), with DNA methylation of the BHMT gene mediating about 35% of the SNP's effect on treatment response — suggesting the variant influences both enzyme function and gene expression.

Interestingly, several studies associate the A allele with protective effects on certain cancers, particularly breast cancer. An analysis of 1,508 breast cancer patients⁷⁷ analysis of 1,508 breast cancer patients
Xu X et al. High intakes of choline and betaine reduce breast cancer mortality. FASEB J, 2009 found rs3733890 carriers had a 36% lower breast cancer-specific mortality (HR 0.64, 95% CI 0.42-0.97). A Chinese case-control study⁸⁸ Chinese case-control study
Du YF et al. Dietary choline and betaine intake and BHMT polymorphisms in breast cancer. Br J Nutr, 2016 found AA postmenopausal women had approximately half the breast cancer risk (OR 0.49), with a significant interaction with choline intake (p=0.006). The protective mechanism may relate to altered methyl-group partitioning away from pro-oncogenic pathways, though this remains mechanistically unresolved.

Developmentally, rs3733890 was significantly associated with omphalocele⁹⁹ significantly associated with omphalocele
Mills JL et al. Folate and vitamin B12-related genes and risk for omphalocele. Hum Genet, 2012 in both African-American and Asian populations in a New York birth cohort study (169 cases, 761 controls). An earlier study found a non-significant protective trend for spina bifida in QQ (AA) children (OR 0.52), coinciding with lower homocysteine in women with the QQ genotype¹⁰¹⁰ women with the QQ genotype
Morin I et al. Common variant in BHMT and risk for spina bifida. Am J Med Genet A, 2003.

Practical Actions

The key intervention for reduced BHMT throughput is ensuring an adequate supply of betaine (trimethylglycine) — the direct methyl donor for the BHMT reaction. When dietary betaine and choline intake is high, the BHMT pathway can run near capacity even with reduced enzyme efficiency. Conversely, low-betaine diets put maximum pressure on the MTHFR/MTR folate pathway, which may not fully compensate if you also carry MTHFR or MTR variants.

Monitoring plasma homocysteine periodically is the most direct way to assess whether your combined methylation pathway capacity is adequate. A result above 10 umol/L warrants optimization of betaine, choline, folate, and B12 intake.

Interactions

BHMT provides an alternative remethylation pathway that can compensate when the MTHFR/MTR pathway is impaired. Individuals who carry both rs3733890 (reduced BHMT) and MTHFR C677T (rs1801133, reduced MTHFR) face a double bottleneck — both major homocysteine recycling routes are compromised simultaneously. The synergistic hyperhomocysteinemia risk in such individuals is likely higher than either variant alone would predict. A study in ADHD families found that the rs3733890 G allele combined with MTRR rs1801394 GG genotype showed elevated homocysteine, pointing to compounding effects in the remethylation network.

BHMT is also zinc-dependent — low zinc status can further impair enzyme function regardless of genotype. The enzyme's outputs (DMG and methionine) feed downstream into the folate and methylation cycles, so rs3733890's effects ripple through the entire one-carbon network.

CYP2B6 is a liver enzyme responsible for metabolizing approximately 8% of prescription drugs, including several critical medications for HIV, pain, depression, and cancer. Despite comprising only 1-4% of total hepatic cytochrome P450 content, CYP2B6 is the primary metabolizer¹¹ CYP2B6 is the primary metabolizer
CYP2B6 is the major catalyst of metabolism for efavirenz, cyclophosphamide, bupropion, methadone, ketamine, and propofol for numerous clinically important drugs. The 516G>T variant (also known as CYP2B6*9 or Q172H) is one of the most common and clinically significant genetic variations in this gene, dramatically reducing enzyme activity and leading to elevated drug levels and increased toxicity risk.

The Mechanism

The 516G>T polymorphism changes codon 172 from glutamine (Q) to histidine (H) in the CYP2B6 protein. The variant triggers aberrant splicing²² The variant triggers aberrant splicing
Single nucleotide polymorphism c.516G>T is responsible for decreased expression and activity of CYP2B6 in liver through aberrant splicing during mRNA processing, resulting in transcripts that lack exons 4-6 and produce non-functional protein. This splicing defect reduces both CYP2B6 mRNA and protein expression in the liver, with homozygous TT carriers showing approximately 70% reduced enzyme activity compared to GG wild-type individuals. The mechanism is dose-dependent: heterozygotes (GT) show intermediate reduction, demonstrating codominant inheritance. This variant is found alone in CYP2B6*9 but also exists in combination with another SNP (785A>G) in the more common CYP2B6*6 allele.

The Evidence

Haas et al. (2004)³³ Haas et al. (2004)
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study studied 157 HIV-infected patients and found homozygosity for 516G>T was present in 20% of African Americans versus 3% of European Americans. The median 24-hour area under the curve of efavirenz was approximately 3-fold higher in TT homozygotes versus GG homozygotes, with intermediate levels in GT heterozygotes. CNS side effects at week 1 were significantly associated with the T allele (p = 0.036). This work established the clinical relevance of the variant and led to CPIC Level A guidelines⁴⁴ CPIC Level A guidelines
Clinical Pharmacogenetics Implementation Consortium guideline for CYP2B6 and efavirenz-containing antiretroviral therapy recommending dose reductions for TT carriers.

For methadone, Kharasch et al. (2015)⁵⁵ Kharasch et al. (2015)
Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism demonstrated that 516G>T genotype was the primary determinant of methadone disposition. In vitro studies showed CYP2B6.6 enzyme activity⁶⁶ CYP2B6.6 enzyme activity
Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6 toward methadone was reduced to one-third to one-fourth that of wild-type enzyme at clinically relevant concentrations. Multiple studies have linked 516G>T with enhanced risk of methadone fatalities⁷⁷ enhanced risk of methadone fatalities
Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities due to accumulation of (S)-methadone, which prolongs the QT interval and increases cardiac risk.

Population frequencies of the T allele vary dramatically by ancestry: approximately 43% in African populations, 28-30% in European and South Asian populations, 29% in Latino populations, and 18% in East Asian populations. This makes the variant one of the most ancestry-differentiated pharmacogenes.

Practical Implications

The 516G>T variant affects multiple drug classes. For HIV treatment with efavirenz, TT carriers experience substantially higher plasma concentrations, increasing risk of neuropsychiatric side effects including dizziness, insomnia, abnormal dreams, confusion, and suicidal ideation. CPIC guidelines recommend considering an alternative antiretroviral or reduced dose (400 mg or 200 mg instead of standard 600 mg daily) for intermediate and poor metabolizers.

For pain management with methadone, slower metabolism leads to drug accumulation, prolonged QT intervals, and increased risk of respiratory depression and cardiac arrhythmias. Dose adjustments and therapeutic drug monitoring are especially important. For depression treatment with bupropion, reduced conversion to the active metabolite hydroxybupropion may diminish antidepressant and smoking cessation efficacy.

For cancer chemotherapy with cyclophosphamide, the clinical implications are complex and substrate-dependent. While 516G>T reduces enzyme expression, some studies suggest the variant may actually increase cyclophosphamide bioactivation through alternative mechanisms, highlighting the substrate-specific nature of CYP2B6 pharmacogenetics.

Interactions

The 516G>T variant (CYP2B6*9) is frequently found in combination with the 785A>G variant, forming CYP2B6*6, the most common reduced-function haplotype globally. The compound effect of these variants produces more severe enzyme deficiency than either alone. Additionally, CYP2B6 activity is highly inducible by rifampin, efavirenz itself, and other drugs, which can partially overcome genetic deficiency but complicates dosing in patients on combination therapy. CYP2B6 polymorphisms may interact with variants in other metabolizing enzymes (CYP3A4, CYP2C19, CYP2D6) that serve as alternative pathways for some substrates, creating complex pharmacokinetic profiles that require careful clinical monitoring.

The MTNR1B gene encodes the melatonin receptor 1B¹¹ melatonin receptor 1B
Also known as MT2, one of two G-protein-coupled receptors for melatonin. MT2 is expressed in the brain (especially the suprachiasmatic nucleus), retina, and pancreatic beta cells, where it mediates melatonin's effects on circadian timing and insulin secretion (MT2), a receptor that links the hormone of darkness to both your sleep-wake cycle and your glucose metabolism. The platform already carries the well-studied rs10830963 — a strong GWAS hit deep within the MTNR1B intron. The rs4753426 variant is different: it sits approximately 1,193 base pairs upstream of the gene's transcription start site, in the promoter, where it directly modulates how much MTNR1B is produced.

The two variants are correlated but not identical. Their linkage disequilibrium is high at the haplotype level (D' = 0.969) but moderate in terms of allele correlation (r² = 0.414), meaning they frequently travel together on chromosomes yet capture partly distinct information. A person who tests positive for one does not necessarily carry the other. The rs4753426 C allele has been independently associated with altered fasting glucose and insulin secretion²² altered fasting glucose and insulin secretion
Staiger H et al. Polymorphisms within the Novel Type 2 Diabetes Risk Locus MTNR1B Determine β-Cell Function. PLoS One, 2008 as well as with a specific circadian phenotype — a preference for mornings and reduced social jetlag — that rs10830963 does not directly capture.

The Mechanism

Promoter variants modulate gene expression rather than protein structure. The -1193 position falls within a region of the MTNR1B promoter that contains binding sites for BMAL1/CLOCK³³ BMAL1/CLOCK
The core transcriptional activators of the circadian clock. BMAL1 and CLOCK form a heterodimer that binds E-box elements in circadian gene promoters to drive rhythmic gene expression, the core circadian transcription factor complex. The C variant at this position alters the binding affinity at or near this element, changing the amplitude of MTNR1B's circadian transcriptional drive. Tissue-level expression data from GTEx indicates that the C allele is associated with altered MTNR1B expression in esophageal mucosa, consistent with a transcriptional rather than protein-level effect.

The downstream consequence mirrors what is seen with rs10830963: elevated MT2 receptor levels in beta cells prolong the window during which melatonin suppresses glucose-stimulated insulin secretion⁴⁴ glucose-stimulated insulin secretion
Melatonin inhibits insulin release by activating inhibitory Gi-proteins on beta cells, reducing cAMP. This is adaptive during sleep but harmful when eating occurs while melatonin is still elevated. The C allele has also been found to modulate circadian entrainment to photoperiod — the frequency of the C allele across human populations correlates with sunshine duration, suggesting an adaptive role in populations at different latitudes.

The Evidence

The original beta-cell function study⁵⁵ original beta-cell function study
Staiger H et al. Polymorphisms within the Novel Type 2 Diabetes Risk Locus MTNR1B Determine β-Cell Function. PLoS One, 2008 of 1,578 non-diabetic subjects found rs4753426 C allele carriers had significantly higher fasting plasma glucose (p < 0.0001) and approximately 20% reductions in IVGTT-derived insulin secretion compared to TT homozygotes. The effect was present alongside — and partially independent from — the rs10830963 signal, reflecting the partial LD between the two variants.

The circadian dimension was established by Pereira e Silva and colleagues⁶⁶ Pereira e Silva and colleagues
Pereira e Silva AC et al. Melatonin receptor 1B -1193T>C polymorphism is associated with diurnal preference and sleep habits. Sleep Medicine, 2019 in 814 subjects, who found the C allele associated with extreme morningness phenotype across codominant, recessive, and allele models, with a negative correlation between the C allele and social jetlag scores. Carriers of the T allele tended to spend more time in bed on weekends — a proxy for accumulated sleep debt and delayed preference.

In gestational diabetes mellitus (GDM), a meta-analysis⁷⁷ meta-analysis
Jia G et al. Effects of MTNR1B Genetic Variants on Individual Susceptibility to Gestational Diabetes Mellitus. Am J Perinatol, 2020 of 17 studies found rs4753426 associated with GDM risk in recessive (OR 1.75) and allele models (OR 0.69), though the associations were less consistent than those for rs10830963, which showed significance across all genetic models.

Practical Implications

The C allele's dual phenotype — morningness plus elevated fasting glucose — suggests that CC carriers wake early (melatonin falls fast) but may still carry some degree of beta-cell vulnerability through the promoter's effect on MTNR1B expression. For CC individuals, the actionable insight is to leverage their natural morning preference: front-loading calories to breakfast and lunch, when their insulin sensitivity is at its best, directly addresses the metabolic vulnerability.

CT heterozygotes have an intermediate profile. The meal-timing principle still applies but with less urgency than for CC homozygotes.

For the circadian angle: CC individuals who experience reduced social jetlag can treat this as a structural advantage — their internal clock is more closely aligned with social time compared to evening chronotypes, reducing the chronic circadian misalignment that independently impairs metabolic function.

Interactions

rs4753426 and rs10830963 operate in partial linkage disequilibrium within the MTNR1B locus. Their D' = 0.969 indicates they rarely appear on different haplotypes, but their r² = 0.414 means they are not interchangeable — carriers of the rs10830963 G allele who are also CC at rs4753426 face compounded promoter-level and intronic expression effects on beta-cell MT2 receptor abundance. The clinical implication is additive: combined, both variants likely produce greater suppression of glucose-stimulated insulin secretion than either alone.

The PTPRS gene encodes receptor protein tyrosine phosphatase sigma (RPTPσ)¹¹ receptor protein tyrosine phosphatase sigma (RPTPσ)
A cell-surface enzyme that belongs to the LAR subfamily of receptor-type phosphatases. It has an extracellular ligand-binding domain and two intracellular catalytic domains, one active and one regulatory, located on chromosome 19p13.3. RPTPσ functions as a negative regulator of tyrosine-kinase-based signalling by removing phosphate groups from tyrosine residues on target proteins. Two of the most important targets in the context of glucose metabolism are the insulin receptor itself and insulin receptor substrate proteins (IRS-1 and IRS-2)²² insulin receptor substrate proteins (IRS-1 and IRS-2)
Adaptor proteins that relay the insulin receptor's signal into the cell's interior; when dephosphorylated by PTPs such as RPTPσ, the downstream signalling cascade is attenuated and insulin sensitivity is reduced.

rs4807015 is an intronic variant — it sits within an intron of PTPRS and does not change any amino acid in the protein. The PTPRS gene is transcribed from the minus strand of chromosome 19, so the genomic (plus-strand) reference allele is T, with C as the alternate allele. The C allele is the risk allele identified in the discovery cohort; it likely acts as a haplotype tag — travelling on the same chromosomal segment as one or more functional changes elsewhere in the gene that upregulate RPTPσ expression or activity.

The Mechanism

Two lines of experimental evidence connect elevated RPTPσ activity to impaired glucose homeostasis. First, in pancreatic beta cells³³ beta cells
The insulin-secreting cells of the pancreatic islets of Langerhans; their capacity to release insulin in response to rising blood glucose is central to preventing type 2 diabetes, RPTPσ dephosphorylates proteins that mediate insulin granule exocytosis, reducing the efficiency of glucose-stimulated insulin secretion. The Goto-Kakizaki spontaneously diabetic rat model shows approximately 60% overexpression of PTP sigma in islets and liver compared with normoglycaemic controls; treating isolated GK islets with antisense oligonucleotides targeting PTP sigma restored glucose-induced insulin secretion to near-normal levels, establishing a direct causal link.

Second, mice lacking PTPRS entirely (RPTPσ knockout mice) display reduced fasting plasma glucose and insulin⁴⁴ reduced fasting plasma glucose and insulin
Chagnon et al. 2006, Canadian Journal of Physiology and Pharmacology — RPTPσ-/- mice showed significantly lower fasting glucose and insulin and enhanced whole-body insulin sensitivity on insulin tolerance testing, consistent with the hypothesis that higher phosphatase activity constrains insulin action in vivo. More recently, pharmacological inhibition of PTPRS and related phosphatases in differentiated muscle cells was shown to increase cellular glucose uptake, pointing toward PTPRS as an actionable target in insulin-resistant tissues.

Epigenetic profiling of islets from pre-diabetic mouse models ranked PTPRS among the strongest predictors of future T2D (area under ROC curve 0.62–0.73), indicating that changes in PTPRS expression at the epigenetic level precede clinical disease onset — consistent with the gene being functionally upstream of the metabolic decline.

The Evidence

The primary human evidence comes from a Swedish Caucasian cohort⁵⁵ Swedish Caucasian cohort
Långberg et al. 2007, European Journal of Endocrinology — 497 subjects with normal glucose tolerance (NGT), 262 with impaired glucose tolerance (IGT), and 298 patients with T2D; all Swedish Caucasians; three PTPRS SNPs tested (n=1,057 total). Among three PTPRS variants tested, rs4807015 was associated with T2D with an odds ratio of 1.74 (p=0.029) across both sexes in logistic regression — the highest sex-combined effect size of the three variants in the study. This is one of the larger effect sizes reported for a common intronic variant in this category; for comparison, the well-replicated TCF7L2 rs7903146 T2D variant typically shows ORs of 1.35–1.45 in European cohorts. The limitation is that this association has not been formally replicated in independent large-scale GWAS data, and the discovery cohort of ~300 T2D cases has limited statistical power. The evidence level is accordingly classified as moderate.

Practical Actions

The C allele is nearly balanced with T in European populations (~48% vs 52%), meaning approximately one in four Europeans is CC homozygous. The actionable concern is that elevated RPTPσ activity attenuates insulin signalling in both beta cells and insulin-sensitive tissues. Interventions that reduce the secretory and metabolic burden — glycaemic load reduction, periodic cardiometabolic monitoring, and proactive fasting insulin testing — are most directly supported by the mechanistic model.

Interactions

PTPRS harbours two other variants associated with T2D in the same Swedish cohort: rs1143699 (synonymous, OR=1.57, strongest in men) and rs1978237 (intronic, OR=1.59, both sexes). All three may tag the same risk haplotype across the PTPRS locus, in which case their effects are not additive. Formal haplotype analysis has not been published. Users carrying risk alleles at multiple PTPRS variants may not face proportionally higher risk, but the co-occurrence strengthens the plausibility of a high-expression PTPRS haplotype.

Deep inside arterial walls, macrophages perform one of the most critical housekeeping tasks in cardiovascular biology: absorbing excess cholesterol from the surrounding tissue and offloading it to high-density lipoprotein (HDL) particles for return to the liver. This reverse cholesterol transport pathway — the body's primary mechanism for clearing arterial cholesterol — depends on the ABCG1 transporter¹¹ ABCG1 transporter
ATP-binding cassette subfamily G member 1, a membrane protein that pumps cholesterol and phospholipids from macrophage cell membranes onto mature HDL particles. When ABCG1 is disrupted, macrophages loaded with cholesterol cannot offload their cargo efficiently. They accumulate cholesterol, become foam cells, undergo accelerated apoptosis, and contribute to the necrotic core of atherosclerotic plaques.

The rs57137919 variant sits in the promoter region of ABCG1 (described as -367G>A in the original literature, consistent with its position upstream of key ABCG1 transcripts on chromosome 21). The G allele at this position is the GRCh38 reference and the population-major allele (~86% globally). It is associated with higher CAD risk in population studies — not because G is pathogenic, but because the less-common A allele confers protection through mechanisms that appear to dominate the macrophage impairment seen in cell studies.

The Mechanism

The rs57137919 G>A substitution reduces the ability of regulatory proteins to bind the ABCG1 promoter region. Luciferase reporter assays²² Luciferase reporter assays confirmed that the A allele impairs promoter-driven transcription, leading to lower ABCG1 mRNA and protein expression in macrophages. At the cellular level, this has measurable consequences: macrophages from A/A donors show 23% less ABCG1-mediated cholesterol efflux and a 2-fold increase in cholesterol-induced apoptosis³³ 23% less ABCG1-mediated cholesterol efflux and a 2-fold increase in cholesterol-induced apoptosis compared to G/G macrophages, with significant upregulation of the pro-apoptotic genes Bok and Bid.

Yet at the population level, A allele carriers have better cardiovascular outcomes. The most likely explanation is that ABCG1 also regulates systemic lipoprotein metabolism in ways that benefit the overall lipid profile: A allele carriers show higher HDL-C and lower LDL-C in multiple Chinese cohort studies. The net effect — better circulating lipid profile — appears to outweigh the macrophage-level efflux impairment in population cardiovascular endpoints. This makes rs57137919 a compelling example of how a single variant can have opposing biological effects at the cellular and systemic levels simultaneously.

The Evidence

The foundational study is Xu et al. 2011 (Atherosclerosis)⁴⁴ Xu et al. 2011 (Atherosclerosis), a case-control study of 1,021 CAD patients and 1,013 controls in a Chinese Han population. A allele carriers had an adjusted OR of 0.73 (p=0.033) for CAD and 0.65 (p=0.014) for myocardial infarction. Among those with CAD, A allele carriers showed less severe angiographic disease (multi-vessel vs single-vessel OR=0.40, p=0.005). The same study confirmed with luciferase assays that the A allele reduces ABCG1 promoter function, establishing the functional basis for the observed association.

The mechanistic detail was expanded by Liu et al. 2014 (PLoS One)⁵⁵ Liu et al. 2014 (PLoS One), which isolated macrophages from human donors stratified by rs57137919 genotype and measured cholesterol efflux and apoptosis directly. G/G macrophages showed the highest efflux capacity; A/A macrophages showed 23% lower efflux and twice the rate of apoptosis when loaded with cholesterol. This cellular impairment is real and biologically significant — it would be expected to accelerate plaque formation in isolation.

On lipid profiles, Wang et al. 2020 (Ann Vasc Surg)⁶⁶ Wang et al. 2020 (Ann Vasc Surg) documented that GA and AA carriers have significantly higher HDL-C (p=0.021) and lower LDL-C (p=0.017) than GG individuals in a Chinese Han cohort. The connection to stroke was confirmed by Yang et al. 2022 (Gene)⁷⁷ Yang et al. 2022 (Gene) — the AA genotype was significantly less common in stroke patients (4.6% vs 13.3% in controls, p=0.030) and associated with the lowest LDL-C levels. In Li et al. 2015⁸⁸ Li et al. 2015, the protective effect was particularly evident in hypertriglyceridemic subjects.

Note that all published studies to date have been conducted in East Asian populations (primarily Chinese Han), which limits direct generalizability to European or African ancestry groups. The biological mechanism is expected to be conserved, but effect sizes in other populations require separate study.

Practical Actions

For GG homozygotes (~74% of people globally): ABCG1 is expressed at full baseline levels in macrophages — reverse cholesterol transport operates without the promoter impairment carried by A allele carriers. The trade-off is that population studies show GG individuals have modestly higher CAD and stroke risk compared to A carriers, driven by less favorable average lipid profiles (lower HDL-C, higher LDL-C). Supporting ABCG1 function and HDL-mediated cholesterol clearance through targeted dietary and lifestyle choices is worthwhile.

For GA heterozygotes (~24%): one A allele partially reduces ABCG1 expression, producing an intermediate effect on both macrophage efflux and lipid profile. HDL-C tends to be mildly higher and LDL-C modestly lower than GG. Monitoring the lipid profile — especially HDL-C and triglycerides together — gives a more complete picture.

For AA homozygotes (~2%): two A alleles produce the largest reduction in ABCG1 expression, the most impaired macrophage cholesterol efflux, and the greatest elevation of macrophage apoptosis. Paradoxically, these individuals also tend to have the most favorable circulating lipid profiles (highest HDL-C, lowest LDL-C) and show the greatest population-level protection from CAD and stroke. The cellular-level macrophage impairment is real and may become clinically relevant under conditions of high dietary cholesterol or pro-inflammatory stress that overwhelms the protective lipid profile advantage.

Interactions

ABCG1 works in concert with ABCA1 in macrophage cholesterol efflux — ABCA1 mediates initial transfer of cholesterol to lipid-poor apoA-I (forming nascent HDL), while ABCG1 loads cholesterol onto mature spherical HDL particles. Variants in ABCA1 (rs4149338) have been studied alongside rs57137919 in stroke research, with opposing directions: ABCA1 variants associated with increased stroke risk while ABCG1 rs57137919 A allele showed protection. The combined effect of ABCG1 and ABCA1 variants on macrophage cholesterol efflux capacity is a candidate for compound action, given that both transporters act sequentially in the same pathway.

The protective effect of the A allele is particularly pronounced in hypertriglyceridemic individuals (Li et al. 2015), suggesting the rs57137919 effect may interact with triglyceride metabolism. ABCG1 participates in VLDL processing and lipoprotein particle remodeling, providing a mechanistic link between this promoter variant and triglyceride pathways — placing it at the intersection of macrophage biology and fatty acid metabolism.

The ANK1 gene encodes ankyrin-1, a cytoskeletal scaffold protein best known for its structural role in red blood cells, where it links membrane proteins to the spectrin cytoskeleton. A second, muscle-specific transcript produces a short isoform called small ankyrin-1 (sAnk1)¹¹ small ankyrin-1 (sAnk1)
sAnk1.5 is a 17-kDa isoform expressed in skeletal muscle sarcoplasmic reticulum; it stabilises the titin filament network and organises the longitudinal sarcoplasmic reticulum. rs6981587 lies within an intronic region of ANK1 on chromosome 8, within a cluster of variants — including rs516946 and rs508419 — that together constitute one of the replicated type 2 diabetes and impaired insulin secretion loci in genome-wide association studies.

The Mechanism

The mechanism at this locus operates through at least two distinct routes. First, a nearby promoter variant (rs508419) increases sAnk1 transcriptional activity in skeletal muscle C2C12 cells²² a nearby promoter variant (rs508419) increases sAnk1 transcriptional activity in skeletal muscle C2C12 cells
Yan et al. 2016: the C allele of rs508419 showed increased luciferase reporter activity and altered DNA-protein binding; human muscle tissue carrying the CCC haplotype showed elevated sAnk1 mRNA. In cells with excess sAnk1 expression, insulin-stimulated glucose uptake is measurably reduced, suggesting that elevated sAnk1 disrupts normal GLUT4³³ GLUT4
Glucose transporter type 4 — the primary insulin-responsive glucose transporter in skeletal muscle; its translocation to the plasma membrane is the key step in insulin-stimulated glucose disposal trafficking or signalling downstream of the insulin receptor.

Second, and perhaps more mechanistically central, genome-wide colocalization analysis identified an adipose ANK1 eQTL at this locus that colocalizes with both the proinsulin GWAS signal and a type 2 diabetes signal (HyPrColoc PPFC = 0.92)⁴⁴ genome-wide colocalization analysis identified an adipose ANK1 eQTL at this locus that colocalizes with both the proinsulin GWAS signal and a type 2 diabetes signal (HyPrColoc PPFC = 0.92)
Broadaway et al. 2023: this near-certainty colocalization means the three signals are almost certainly driven by the same causal variant, pointing to adipose-expressed ANK1 as the effector gene. Notably, this adipose eQTL signal does NOT colocalize with the islet NKX6-3 eQTL, implying that the diabetes-relevant effect originates in adipose tissue rather than the pancreas — an unusual route to impaired insulin processing and T2D risk. How adipose ANK1 expression regulates circulating proinsulin remains an open question, but altered lipid storage capacity, adipokine signalling, or structural changes in the adipocyte membrane are plausible intermediaries.

The Evidence

The clearest functional evidence comes from Yan et al. 2016⁵⁵ Yan et al. 2016
Yan Y, Wang F, Xie T et al. A novel type 2 diabetes risk allele increases the promoter activity of the muscle-specific small ankyrin 1 gene. Sci Rep. 2016;6:25105. A two-stage case-control GWAS identified a CCC haplotype spanning this region with T2D odds ratio 1.447 (p < 0.001). Functional validation confirmed the rs508419-C allele increases sAnk1 promoter activity and that excess sAnk1 in human C2C12 myotubes reduces insulin-stimulated glucose uptake.

Beta-cell function effects at this locus were characterised by Harder et al. 2013⁶⁶ Harder et al. 2013
Harder MN et al. Type 2 diabetes risk alleles near BCAR1 and in ANK1 associate with decreased β-cell function. J Clin Endocrinol Metab. 2013;98(4):E801-6. In 5,739 Danish Inter99 participants, the ANK1 rs516946 C allele was associated with a decreased insulinogenic index (p = 0.005) and a decreased disposition index (p = 0.002), indicating a small but consistent impairment in beta-cell response to glucose — an effect replicated in a Chinese cohort where rs516946 conferred OR 1.39 for impaired insulin release (95% CI 1.07–1.81).

A sex-specific interaction was found by Zhu et al. 2022⁷⁷ Zhu et al. 2022
Zhu J et al. The SNP rs516946 interacted in the association of MetS with dietary iron among Chinese males but not females. Nutrients. 2022;14(10):2024. Among 1,284 Chinese men, T allele non-carriers (CC) showed a direct association between dietary iron intake and metabolic syndrome risk; this relationship was absent in T allele carriers, suggesting that the ANK1 variant modifies iron-related metabolic pathways — potentially through hepatic mechanisms, as AST elevations tracked with the variant in this cohort. Women showed no such interaction, possibly due to menstruation-mediated iron cycling.

One cautionary note: a 2026 mouse study found no difference in glucose handling in double-transgenic mice overexpressing both miR-486-5p and sAnk1.5 under standard and high-fat diets⁸⁸ found no difference in glucose handling in double-transgenic mice overexpressing both miR-486-5p and sAnk1.5 under standard and high-fat diets
Buonocore et al. 2026: PMID 41260536, suggesting that the T2D mechanism at this locus may not operate through sAnk1 overexpression alone. The adipose eQTL hypothesis remains the stronger candidate.

Practical Actions

The insulin secretion impairment at this locus is modest compared with the beta-cell effects at KCNJ11 or TCF7L2. The most relevant intervention is avoiding factors that compound the impaired insulin processing signal: specifically, high dietary iron intakes appear to interact with the T allele to increase metabolic syndrome risk in men. Monitoring fasting insulin and proinsulin-to-insulin ratio can detect early impairment in insulin processing. For TT homozygotes carrying the maximum allele dose, annual fasting metabolic screening is warranted.

Interactions

rs6981587 sits within the same intronic cluster as rs516946 (chr8:41,661,730) and rs508419 (chr8:41,665,473). These variants likely tag the same underlying causal variant — the adipose ANK1 eQTL — rather than representing independent effects. rs13412852 in the nearby LPIN1 gene (chromosome 2) shows a nominal BMI association and represents a separate fat-metabolism pathway; no interaction between the ANK1 locus and LPIN1 variants has been documented. The dietary iron × rs516946 interaction described by Zhu et al. suggests that high-iron dietary patterns may amplify risk at this locus, warranting a gene–nutrient interaction with iron intake monitoring.

Every time you encounter a stressor, your adrenal glands flood your bloodstream with cortisol¹¹ cortisol
The primary glucocorticoid stress hormone, released by the adrenal cortex in response to HPA axis activation. Cortisol mobilizes energy, suppresses immunity, and is meant to resolve quickly through a negative feedback loop. The cortisol signal is supposed to shut itself off — negative feedback through the HPA axis²² HPA axis
The hypothalamic-pituitary-adrenal axis: the hormonal cascade where the hypothalamus releases CRH → pituitary releases ACTH → adrenal glands release cortisol. Cortisol then feeds back to suppress CRH and ACTH, terminating its own release keeps the stress response time-limited. FKBP5 is a critical governor of this feedback circuit, and rs9470080 is one of several variants in the gene that determine how well the circuit works.

This SNP is part of a four-variant haplotype block in FKBP5 — alongside rs3800373, rs9296158, and rs1360780 — that researchers call the H2 "risk" haplotype. All four variants are in high linkage disequilibrium³³ linkage disequilibrium
A genetic term for when variants tend to be inherited together more often than chance predicts, because they sit close together on the chromosome and are rarely separated by recombination. High LD means the four FKBP5 risk alleles travel as a unit with each other (r² > 0.7), meaning carriers of the T allele at rs9470080 almost always also carry the risk alleles at the other three loci. The clinical significance of rs9470080 therefore reflects not just this single SNP but the combined dosage effect of the entire haplotype block.

What makes rs9470080 worth knowing about in the context of longevity and aging is the mounting evidence that FKBP5 sits at the biological intersection of chronic stress and cellular aging. Zannas et al. (2019)⁴⁴ Zannas et al. (2019)
Zannas AS et al. Epigenetic upregulation of FKBP5 by aging and stress contributes to NF-κB-driven inflammation and cardiovascular risk. PNAS, 2019 showed across cohorts totaling 3,131 individuals that aging and stress synergistically demethylate FKBP5 regulatory regions — including around the rs9470080 locus — upregulating FKBP5 expression and driving NF-κB⁵⁵ NF-κB
Nuclear factor kappa-light-chain-enhancer of activated B cells — a master transcription factor for pro-inflammatory genes including IL-6, TNF-α, and IL-1β. Chronic NF-κB activation is a hallmark of inflammaging — the low-grade sterile inflammation associated with biological aging-mediated inflammation and cardiovascular risk.

The Mechanism

FKBP5 encodes FK506-binding protein 51, a co-chaperone⁶⁶ co-chaperone
A helper protein that works alongside main chaperones such as hsp90 to fold client proteins into their correct shape. FKBP51's client is the glucocorticoid receptor, and by modulating it FKBP51 controls how sensitive cells are to cortisol of the glucocorticoid receptor⁷⁷ glucocorticoid receptor
The intracellular receptor for cortisol and other glucocorticoids. When cortisol binds GR in the cytoplasm, the activated complex translocates to the nucleus and changes expression of hundreds of genes — including FKBP5 itself, creating a feedback loop (GR). When cortisol rises, FKBP5 expression increases; more FKBP51 protein then inhibits GR from returning to the nucleus, which dampens cortisol's ability to switch off its own production. This creates a proportional brake on the stress response.

The T allele at rs9470080 is part of the CATT haplotype that strengthens this positive feedback: the risk haplotype as a whole creates stronger glucocorticoid response elements⁸⁸ glucocorticoid response elements
DNA binding sites for the activated glucocorticoid receptor complex. Stronger GREs mean cortisol more potently switches on FKBP5 transcription, amplifying the inhibitory co-chaperone and slowing cortisol clearance from the system at intronic regulatory regions, leading to greater FKBP5 upregulation per unit of cortisol. T-allele carriers produce more FKBP51 in response to stress, which more potently suppresses GR sensitivity, which slows the negative feedback loop that should terminate the cortisol response. The net result: cortisol stays elevated longer after each stressor.

Beyond acute stress response, the epigenetic aging component is mechanistically distinct. With advancing age, CpG methylation across the FKBP5 locus progressively decreases — a change accelerated by chronic psychological stress. Lower methylation means higher basal FKBP5 expression independent of cortisol. This age-amplified FKBP5 upregulation then activates IKK complex assembly⁹⁹ IKK complex assembly
The kinase complex that phosphorylates IκB, releasing NF-κB to enter the nucleus and activate inflammatory gene transcription. FKBP51 promotes IKK assembly through its TPR domain, directly linking HPA axis dysregulation to chronic inflammation, driving persistent low-grade inflammation — the "inflammaging¹⁰¹⁰ inflammaging
The chronic, low-grade, sterile inflammatory state that accumulates with aging and underlies most age-related diseases including cardiovascular disease, type 2 diabetes, neurodegeneration, and cancer. Distinct from acute inflammation, which resolves; inflammaging persists and slowly damages tissues" phenotype characteristic of biological aging. T-allele carriers who have accumulated stress across their lifetimes are most vulnerable to this epigenetic-inflammatory cascade.

The Evidence

rs9470080's associations with stress-related phenotypes are firmly established across multiple independent cohorts.

Binder et al. (2008)¹¹¹¹ Binder et al. (2008)
Binder EB et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA, 2008 demonstrated in 900+ individuals that the four-SNP haplotype including rs9470080 significantly interacted with childhood adversity to predict adult PTSD severity . Without childhood trauma, haplotype did not predict PTSD. With high abuse exposure, carriers of the risk haplotype had dramatically elevated risk — establishing this as a textbook diathesis-stress interaction.

Wang et al. (2018)¹²¹² Wang et al. (2018)
Wang Q et al. Interaction between early-life stress and FKBP5 gene variants in MDD and PTSD: a systematic review and meta-analysis. J Affect Disord, 2018 pooled 14 studies totaling 15,109 participants and confirmed the gene-environment interaction, finding that

FKBP5 risk haplotype carriers exposed to early-life stress had significantly elevated MDD and PTSD risk compared to non-carriers with similar trauma histories .

Binder et al. (2014)¹³¹³ Binder et al. (2014)
Binder EB et al. FKBP5 polymorphism is associated with major depression but not with bipolar disorder. J Affect Disord, 2014 specifically confirmed rs9470080's association with MDD in a study of 1,274 participants (513 MDD, 216 BD, 545 controls), and used multifactor dimensionality reduction¹⁴¹⁴ multifactor dimensionality reduction
A data-mining method that identifies combinations of genetic variants whose joint effect predicts disease better than any variant alone — particularly useful for detecting epistatic interactions (gene-gene effects) to identify a

significant gene-gene interaction between FKBP5 rs9470080 and NR3C1 rs6198 — the glucocorticoid receptor's own regulatory variant — on MDD susceptibility .

Roy et al. (2010)¹⁵¹⁵ Roy et al. (2010)
Roy A et al. Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. Neuropsychopharmacology, 2010 found rs9470080 showed

a significant main effect on suicide attempt risk . Among those with high childhood trauma exposure, 51% carrying two copies of the risk haplotype had attempted suicide, compared to 36% with one copy and 20% with none.

The Zannas et al. (2019) PNAS study added a critical aging dimension: across four independent cohorts (total N=3,131), greater chronological age and cumulative stress load were synergistically associated with

epigenetic derepression at the FKBP5 locus, driving NF-κB-mediated inflammation and independently predicting cardiovascular event risk . This is the mechanistic bridge between stress-related epigenetic changes at FKBP5 and cardiovascular aging.

Practical Actions

The most actionable insight from this SNP concerns the management of chronic physiological stress over decades. For T-allele carriers, each prolonged stress exposure has a modestly amplified epigenetic cost — greater methylation loss at FKBP5 regulatory regions, more persistent HPA axis activation, and greater inflammatory signaling. The cumulative effect across a lifetime is measurable in cardiovascular and metabolic outcomes.

The evidence base most strongly supports approaches that dampen allostatic load¹⁶¹⁶ allostatic load
The cumulative physiological wear-and-tear from repeated or chronic stress exposure. High allostatic load accelerates biological aging and predicts cardiovascular disease, cognitive decline, and premature mortality: regular aerobic exercise (which reduces HPA reactivity and improves cortisol clearance), consistent sleep (which normalizes HPA axis rhythm), and evidence-based stress reduction techniques including mindfulness- based stress reduction (MBSR) and cognitive-behavioral approaches.

For those with a history of early-life adversity, monitoring of inflammatory markers (hsCRP, IL-6) and cortisol rhythms (waking cortisol, cortisol awakening response) provides early signals of HPA dysregulation before clinical disease manifests. FKBP5 T-allele carriers in the context of childhood trauma represent the highest-risk subgroup for stress-related premature aging.

Ashwagandha (KSM-66 extract, 300–600 mg/day) has demonstrated significant cortisol- lowering effects in RCTs of chronically stressed adults. Phosphatidylserine (400–800 mg/day) has evidence for blunting cortisol responses to psychological stress. These supplements address the downstream consequences of FKBP5 overactivity, not the variant itself, and should be used as part of a broader stress management strategy.

Interactions

rs9470080 sits in the same haplotype block as rs1360780, rs3800373, and rs9296158 — these four variants travel together in high LD and represent coordinated aspects of the FKBP5 functional risk haplotype. Carrying the T allele at rs9470080 very likely means carrying the T allele at rs1360780 as well.

The gene-gene interaction with NR3C1 rs6198¹⁷¹⁷ NR3C1 rs6198 is documented. NR3C1 rs6198 increases expression of GRβ, the dominant-negative glucocorticoid receptor isoform that blunts cortisol signaling. The combination of FKBP5 rs9470080 T (impaired GR cortisol feedback through FKBP51 overactivity) and NR3C1 rs6198 C (reduced GR signaling through GRβ dominance) creates compounding dysregulation of the HPA axis from two directions — excessive FKBP51 inhibiting GR activity, and GRβ competitively suppressing GRα. Together, these produce more severe HPA axis feedback failure than either variant alone, as confirmed by multifactor dimensionality reduction analysis in a case-control MDD study.

For interactions with COMT rs4680¹⁸¹⁸ COMT rs4680: COMT Val158Met (slow COMT / Met allele) reduces catecholamine clearance. Combined with FKBP5 rs9470080 T allele's prolonged cortisol response, both the glucocorticoid and catecholamine arms of the stress response are extended — a dual pathway to elevated allostatic load.

Interleukin-4 (IL-4) is the master switch of the Th2 immune axis — it instructs naive T cells to differentiate into Th2 cells, drives B cells to switch antibody production to IgE, and sustains the eosinophil and mast cell responses that underlie asthma, atopic dermatitis, and allergic rhinitis. The rs2243290 variant¹¹ rs2243290 variant
An intronic single-nucleotide variant located within intron 3 of the IL4 gene on chromosome 5 does not alter the protein sequence, but it sits within a haplotype block that has measurable consequences for allergic disease susceptibility. Understanding this SNP requires understanding the haplotype it belongs to.

The Mechanism

rs2243290 is one of three variants that together define the IL4 protective C-G-C haplotype, alongside rs2243250²² rs2243250
The IL4 -589C>T promoter variant — the best-studied IL4 regulatory SNP, which alters NFAT-1 transcription factor binding affinity and rs2227284³³ rs2227284
An IL4 intron 2 variant whose GG genotype has independently shown protective effects against rhinoconjunctivitis. When all three loci carry their protective alleles (C at rs2243250, G at rs2227284, C at rs2243290), the resulting haplotype is associated with lower Th2 tone and reduced atopic risk. The intronic location of rs2243290 means it likely influences IL4 expression through regulatory mechanisms — possibly affecting pre-mRNA splicing efficiency, intronic enhancer activity, or chromatin state at the locus — rather than changing the protein. The precise molecular mechanism through which this specific intronic variant contributes to haplotype function has not been fully resolved in published literature; the evidence is haplotypic rather than mechanistically isolated to this SNP alone.

The Evidence

The most direct evidence for rs2243290 itself comes from a 2013 Japanese case-control study⁴⁴ 2013 Japanese case-control study
Miyake, Tanaka & Arakawa — J Investig Allergol Clin Immunol 2013; 89 asthmatic women, 1,281 controls. The AC genotype at rs2243290 was significantly associated with a reduced risk of asthma (adjusted OR 0.62, 95% CI 0.39–0.996) compared to the AA reference group. The CC genotype did not reach significance, likely because the C allele is rare in East Asian populations (~26%) — the study lacked power for the CC group. Notably, haplotype-level analyses including this SNP alongside rs2243250 and rs2227284 did not reach formal significance, suggesting the individual SNP signal may be partly independent of or partly redundant with the full haplotype.

A companion study of 393 rhinoconjunctivitis cases vs 703 controls⁵⁵ 393 rhinoconjunctivitis cases vs 703 controls
Miyake, Tanaka & Arakawa — Hum Immunol 2012 found no significant association with rs2243290 and allergic rhinitis, while rs2227284 GG remained protective (OR 0.60). This divergence in phenotype associations is consistent with the complex, tissue-specific nature of IL4 regulation in different allergic manifestations.

The broader context is that IL4 pathway variants combine additively and synergistically. A four-locus interaction study in 2,000 Han Chinese children⁶⁶ four-locus interaction study in 2,000 Han Chinese children
Li Hua et al., Pediatric Pulmonology 2016 found that children homozygous for risk alleles at IL4 rs2243250, IL13, FCER1B, and ADRB2 had OR 13.55 for asthma — illustrating how the cumulative Th2 haplotype burden, of which rs2243290 is one component, drives exponential risk escalation.

Practical Actions

For those carrying one or two A alleles at rs2243290, the practical significance depends on the broader IL4 haplotype context: AA homozygotes (common in East Asian populations but rare in Europeans) lack protective alleles at this intronic locus and, if they also carry the rs2243250 T allele and rs2227284 T allele, represent the highest-risk IL4 haplotype profile. Monitoring total serum IgE when allergic symptoms develop is the most clinically actionable response to this genotype. Quercetin — which demonstrably suppresses IL-4 transcription in activated T cells — has indirect mechanistic relevance since this intronic variant is part of the same regulatory architecture as the promoter variants that quercetin modulates.

Interactions

rs2243290 should be interpreted in concert with its haplotype partners: rs2243250 (IL4 -589C>T promoter, the primary Th2 amplification signal) and rs2227284 (IL4 intron 2, protective GG). The combination of risk alleles across these three loci (TT at rs2243250, TT at rs2227284, AA at rs2243290) defines the high-Th2 IL4 haplotype. Additionally, the downstream IL-4 receptor variant rs1801275 (IL4R Gln576Arg) and the IL-13 variant rs20541 (IL13 Arg130Gln) create additive Th2 amplification when present alongside IL4 haplotype risk alleles.

The IL7R gene¹¹ IL7R gene
IL7R encodes the interleukin-7 receptor alpha chain (IL-7Rα, CD127), which together with the common gamma chain (γc) forms the heterodimeric receptor that binds IL-7 on chromosome 5p13.2 encodes the interleukin-7 receptor alpha chain, an indispensable regulator of T-cell development and homeostasis. The GeneOps database already includes rs6897932 (T244I)²² rs6897932 (T244I)
The exon 6 splicing variant that shifts the membrane-to-soluble receptor balance, raising sIL7R production and amplifying IL-7 signaling, the best-characterized IL7R multiple sclerosis locus. rs3194051 represents a second coding variant in the same gene — an exon 8 missense change, Ile356Val (c.1066A>G) — identified in the same discovery sequencing effort and studied in multiple subsequent association analyses.

Unlike its more famous sibling, rs3194051 (I356V) sits in exon 8, which encodes part of the intracellular domain of IL-7Rα. Isoleucine 356 lies downstream of the transmembrane anchor, in the region responsible for intracellular signaling and association with the JAK1 kinase. The conservative Ile→Val substitution maintains the nonpolar character of this residue, and no functional effect on receptor expression, splicing, JAK1 binding, or IL-7-driven JAK-STAT signaling has been demonstrated³³ no functional effect on receptor expression, splicing, JAK1 binding, or IL-7-driven JAK-STAT signaling has been demonstrated
In contrast, rs6897932 has a well-characterised splicing mechanism with multiple independent validations. This mechanistic gap is the central reason the evidence for rs3194051 is classified as moderate rather than strong.

The Mechanism

Valine and isoleucine are both branched-chain aliphatic amino acids with nearly identical physicochemical properties — the only structural difference is one methylene group. Position 356 is within the intracellular Box 1–Box 2 motif region that participates in JAK1 association and downstream phosphorylation of STAT5⁴⁴ JAK1 association and downstream phosphorylation of STAT5
JAK-STAT signaling is the principal pathway by which IL-7 promotes T-cell survival, proliferation, and differentiation. Computational tools (SIFT, PolyPhen) classify this substitution as tolerated/benign, consistent with the lack of observed functional differences in cell-based assays. ClinVar records this variant as Benign based on three submissions.

The working hypothesis for its MS association — where it has been detected — is that it may act as a tag for nearby regulatory or structural variants in the IL7R locus not yet fully resolved by sequencing, or that it contributes to a polygenic haplotype effect in the context of rs6897932 and other IL7R variants. In the original Swedish discovery study, rs3194051 and rs987107 were identified together as a second IL7R risk haplotype distinct from the rs6897932 haplotype, with rs3194051 G allele frequency being approximately 9% higher in MS cases than controls.

The Evidence

The original identification of rs3194051 came from Zhang et al. 2005⁵⁵ Zhang et al. 2005
Sequencing of IL7R coding exons in Swedish MS cases and controls; both rs3194051 and rs987107 showed significantly higher G allele frequency in cases (~9% excess), who sequenced IL7R coding exons in Swedish MS cases and controls and found the G allele at rs3194051 significantly enriched in cases. However, subsequent independent studies gave conflicting results — several found no significant association, while others observed modest effects consistent with the Swedish finding.

A meta-analysis of eight studies⁶⁶ meta-analysis of eight studies
7,292 MS cases and 8,142 healthy controls pooled; recessive model OR 1.17 (95% CI 1.02–1.33), P < 0.05 gave a borderline-significant recessive OR of 1.17, consistent with the GG homozygote driving any signal. The larger meta-analysis of 27 studies with 9,734 cases and 10,436 controls⁷⁷ 27 studies with 9,734 cases and 10,436 controls
Three IL7RA loci significantly associated with MS: rs6897932, rs3194051, and a third; rs3194051 recessive OR 1.22 (95% CI 1.08–1.38) found OR 1.22 under the recessive model, reaching conventional significance. The signal is weaker than rs6897932 (which achieves genome-wide significance in GWAS), and it is not consistently detected across all ancestry groups or study designs.

Beyond MS, an analysis of HIV/HCV-coinfected patients⁸⁸ an analysis of HIV/HCV-coinfected patients
Cross-sectional study examining IL7R polymorphisms and liver fibrosis severity in 259 HIV/HCV-coinfected patients found that the AA genotype at rs3194051 was associated with significantly higher odds of severe fibrosis, suggesting that IL-7 signaling through this receptor variant modulates immune-driven hepatic damage. This finding adds biological plausibility — even if the mechanism is not proven — by demonstrating that rs3194051 genotype tracks clinically with IL-7-pathway-dependent immune responses.

The GG genotype, which drives the recessive MS association, occurs in approximately 7% of Europeans (consistent with a G allele frequency of ~27% and Hardy-Weinberg equilibrium). In East Asian populations the G allele frequency drops to approximately 6%, making GG homozygotes extremely rare (~0.4%) in these groups, which partly explains why the MS association is detected primarily in European Caucasian cohorts.

Practical Actions

Given the recessive model of association, practical implications are concentrated in GG homozygotes. The absolute excess MS risk conferred by GG at this locus is modest — OR 1.22 over the AA+AG background is smaller than the rs6897932 CC genotype effect and operates on top of the much larger HLA-DRB1*15:01 contribution. Nevertheless, GG carriers who also carry rs6897932 CC (the primary IL7R risk genotype) may have a cumulative IL7R haplotype burden worth considering in the context of other MS genetic risk factors.

The principal actionable parallel is maintaining adequate vitamin D levels, which is the most consistently supported modifiable factor for MS risk reduction and is independently recommended across all IL7R and other immune MS loci. No variant-specific intervention exists for I356V.

For AA homozygotes — the most common genotype — the hepatic fibrosis finding in HIV/HCV coinfection is of specific relevance: if you are coinfected with both viruses, this genotype identifies a subgroup at higher risk of accelerated liver disease, a consideration for timing and intensity of antiviral treatment.

Interactions

The primary IL7R MS haplotype interaction is with rs6897932. The two variants are in partial linkage disequilibrium within the IL7R locus⁹⁹ partial linkage disequilibrium within the IL7R locus
Both variants are in exonic coding sequence; the exon 6 splice-disrupting rs6897932 and the exon 8 missense rs3194051 are on the same chromosome but not in complete LD, allowing independent haplotype combinations, and individuals who carry risk alleles at both loci may have a cumulative IL7R susceptibility haplotype. The I356V variant was co-identified with rs987107 (another IL7R intronic/regulatory variant) in the original Swedish discovery study, and these three variants together may tag a broader IL7R risk haplotype that encompasses both exon 6 splicing dysregulation and exon 8 structural effects.

Outside IL7R, the gene-gene interaction framework established for rs6897932 — where co-occurrence with IL2RA rs2104286 or DDX39B rs2523506 risk alleles multiplies MS risk — likely extends to any IL7R risk haplotype that reduces effective membrane-bound receptor availability or increases aberrant IL-7 signaling. Individuals carrying GG at rs3194051 alongside CC at rs6897932 are expected to lie at the high end of IL7R-mediated MS susceptibility from this gene alone.

CYP2C19 is one of the most pharmacogenomically important enzymes in the human body, metabolizing drugs as diverse as the antiplatelet agent clopidogrel, antifungals like voriconazole, proton pump inhibitors (PPIs), and multiple antidepressants. The rs3758581 variant encodes an isoleucine-to-valine substitution at position 331 ¹¹ p.Ile331Val, c.991A>G and defines part of the CYP2C19*1B allele classification. Understanding this variant requires recognizing that most people carry the Val331 form (G allele), while the ancestral Ile331 form (A allele) is the rarer variant found predominantly in South Asian populations and in backgrounds that include loss-of-function haplotypes.

The Mechanism

The Ile331Val substitution occurs in a substrate-binding region of the CYP2C19 protein. Val331 (the G allele, *1B-associated) represents the common population form and is associated with normal enzyme function. The rarer Ile331 form (A allele) frequently co-occurs on haplotypes that carry other loss-of-function variants, most notably CYP2C19*2 (rs4244285)²² CYP2C19*2 (rs4244285) — the splice-site variant that abolishes enzyme activity. As noted by Yaşar (2018)³³ Yaşar (2018)
Yaşar Ü. The role of pharmacogenetics of cytochrome P450s in phenytoin-induced DRESS syndrome. Cent Eur J Immunol, 2018, rs3758581 "may be present in 40 different haplotypes of CYP2C19 including *2 and *17," which is why full haplotyping — not this single variant alone — gives the definitive metabolizer phenotype.

The Evidence

Cardiovascular pharmacogenomics: CYP2C19 metabolizer status is most clinically impactful for clopidogrel, the antiplatelet prodrug. The 2022 CPIC guideline update for clopidogrel⁴⁴ 2022 CPIC guideline update for clopidogrel
Lee CR et al. CPIC guideline for CYP2C19 and clopidogrel. Clin Pharmacol Ther, 2022 documents that intermediate metabolizers (one reduced-function allele) have elevated risk of major adverse cardiovascular events, and recommends considering alternative antiplatelet agents such as prasugrel or ticagrelor.

Acid suppression: For proton pump inhibitors, the CPIC PPI guideline⁵⁵ CPIC PPI guideline
Lima JJ et al. CPIC guideline for CYP2C19 and PPI dosing. Clin Pharmacol Ther, 2021 recommends genotype-guided dosing, with dose increases for rapid/ultrarapid metabolizers and dose considerations for poor metabolizers taking chronic PPI therapy.

Antifungal therapy: Voriconazole trough concentrations vary up to 10-fold based on CYP2C19 genotype. The CPIC voriconazole guideline⁶⁶ CPIC voriconazole guideline
Moriyama B et al. CPIC guidelines for CYP2C19 and voriconazole. Clin Pharmacol Ther, 2017 recommends dose adjustment and therapeutic drug monitoring across all non-normal metabolizer phenotypes.

Antidepressants: CYP2C19 metabolizes citalopram, escitalopram, sertraline, and other SSRIs. The 2023 CPIC antidepressant guideline⁷⁷ 2023 CPIC antidepressant guideline
Bousman CA et al. CPIC guideline for CYP2C19 and serotonin reuptake inhibitors. Clin Pharmacol Ther, 2023 provides genotype-guided selection and dosing recommendations.

Population context: rs3758581 was significantly associated with warfarin weekly dose⁸⁸ significantly associated with warfarin weekly dose
Ammari MA et al. Pharmacogenomics J, 2023 in 786 Saudi patients, highlighting population-specific pharmacogenomic implications.

Practical Actions

Because the A allele at this position frequently marks haplotypes carrying the *2 loss-of-function allele (rs4244285), carriers of the A allele — particularly homozygous AA individuals — benefit from comprehensive CYP2C19 haplotyping before starting any CYP2C19-substrate drug. The clinical management decisions ultimately depend on the full metabolizer phenotype (normal, intermediate, or poor), not this single variant in isolation.

Interactions

This variant sits in the same gene as CYP2C19*2 (rs4244285) and CYP2C19*3 (rs4986893), which are the primary loss-of-function alleles, and CYP2C19*17 (rs12248560), the gain-of-function promoter variant. The rs3758581 A allele is in linkage disequilibrium with *2-containing haplotypes in many populations, meaning a homozygous AA individual is more likely than chance to also carry *2. Full diplotype testing resolves this ambiguity. CYP2C8 variants (e.g. rs1934953) also influence drug metabolism in the same chromosomal region and can compound pharmacogenomic effects.